AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00249821
Drug: Saizen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saizen® \[somatropin (rDNA origin) for injection\], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
Trial: NCT03995121
Drug: [11C]APP311
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
Trial: NCT01500122
Drug: RhuDex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions.
Trial: NCT02280070
Drug: l-LV
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
Trial: NCT00659048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00576017
Drug: Fentanyl-TTS
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00525967
Drug: Methadone plus Acetaminophen or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
Trial: NCT00357357
Drug: HF0220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT01669499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00306215
Drug: CCX282-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX282-B or placebo capsules
Trial: NCT01031381
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
Trial: NCT01210131
Drug: [18F]HX4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection
Trial: NCT02995031
Drug: BAY987521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-177)
Trial: NCT02995031
Drug: SPF Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Trial: NCT01640912
Drug: RXI-109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intradermal injection of RXI-109 at incision sites
Trial: NCT01640912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intradermal injection of placebo at incision sites
Trial: NCT01651858
Drug: Nurigra Chewable tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of 100mg, once a day
Trial: NCT02081404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02698748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
Trial: NCT00978549
Drug: steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01878942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing mannitol looking identical to LSD~per os
Trial: NCT02720770
Drug: norditropine simplex
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01823146
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
Trial: NCT00398918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT02140450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tears, 2 drops, 1-2 hours before intravitreal injection
Trial: NCT01350921
Drug: Venlaflaxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg oral immediate release tablets, administered twice daily on days 4-8
Trial: NCT00365261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2 to 3 mg po at bedtime
Trial: NCT00366977
Drug: NRT patches
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03644095
Drug: Mucinex® SE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
Trial: NCT01802086
Drug: Miniderm cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT02833350
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
Trial: NCT02833350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
Trial: NCT02668692
Drug: LEO 80185 gel
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: calcipotriol hydrate 52.2 µg/g \[equivalent to 50.0 µg/g calcipotriol\] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
Trial: NCT04432506
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03327012
Drug: Treatment of Panlongqi placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
Trial: NCT00075595
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00075595
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00075595
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01957774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02650635
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00569465
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg, once a day
Trial: NCT00569465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 vials a day
Trial: NCT01604408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03242889
Drug: DARA SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
Trial: NCT02508857
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
Trial: NCT02484833
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02023593
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Trial: NCT01955564
Drug: NW-3509a
RxNorm normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT03758443
Drug: TD-1473 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm description
Trial: NCT03758443
Drug: TD-1473 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm description
Trial: NCT03758443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm description
Trial: NCT04432259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo
Trial: NCT00471146
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02387710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00120523
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCS
Trial: NCT00000304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00949130
Drug: NXL103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID for 7-14 days
Trial: NCT03780543
Drug: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved package insert.
Trial: NCT00092157
Drug: MK0733, simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092157
Drug: Comparator: simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03987022
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of non-steroidal anti-inflammatory drug for pain control postoperatively
Trial: NCT03987022
Drug: Opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of narcotic for pain control postoperatively
Trial: NCT03987022
Drug: Dilaudid Injectable Product
RxNorm normalized name: Dilaudid Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of narcotic for pain control postoperatively
Trial: NCT03987022
Drug: Percocet 5Mg-325Mg Tablet
RxNorm normalized name: Percocet 5mg-325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of combination tablet of Tylenol and Oxycodone for pain control postoperatively
Trial: NCT02098629
Drug: Saline Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
Trial: NCT00335816
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00335816
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01380028
Drug: oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
Trial: NCT01380028
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02607800
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100/100 mg tablet administered orally once daily with food
Trial: NCT02607800
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg tablet administered orally once daily with or without food
Trial: NCT02001103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
Trial: NCT00492089
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00446420
Drug: Propofol, midazolam, fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
Trial: NCT00516074
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, volume equivalent to active, twice a day
Trial: NCT01589978
Drug: P2Y12 antagonist
RxNorm normalized name: Purinergic receptor subtype P2Y12 antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~* Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~* Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce ticagrelor effectiveness and should be avoided.~* Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)
Trial: NCT00278512
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Causes prevention of the cell division
Trial: NCT00278512
Drug: Campath-1h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized monoclonal antibody against CD52 antigen
Trial: NCT01480648
Drug: BI 144807 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo that represents BI drug
Trial: NCT02272478
Drug: Arm A Mylotarg plus DA Versus CPX-351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
Trial: NCT02189083
Drug: TSD
RxNorm normalized name: TSD Pt Cap-Red 33mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks.
Trial: NCT02272478
Drug: Arm D Small molecule or Not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
Trial: NCT03556371
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
Trial: NCT03674008
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
Trial: NCT02294071
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral liquid ibuprofen 10mg/kg (maximum 600 mg)
Trial: NCT02294071
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral liquid acetaminophen 15mg/kg (max 975mg)
Trial: NCT01903031
Drug: ATV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
Trial: NCT01903031
Drug: NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
Trial: NCT04468607
Drug: BLYG8824A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLYG8824A will be administered at a flat dose independent of body weight.
Trial: NCT03078400
Drug: SPL-108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 150 mg administered either one time or two times per day.
Trial: NCT01193270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water in volume equal to that of the comparator drug
Trial: NCT00392080
Drug: CJ-023,423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg BID
Trial: NCT00392080
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00392080
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen
Trial: NCT00663910
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
Trial: NCT02158975
Drug: MLN9708
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03000569
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa (including carbidopa-levodopa) administered as antiparkinsonian agent(s).
Trial: NCT03112356
Drug: 99mTc-Leukoscan® scintigraphy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
Trial: NCT03917628
Drug: SCT630
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT630 single s.c. injection
Trial: NCT01226316
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
Trial: NCT01226316
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
Trial: NCT01226316
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
Trial: NCT01226316
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
Trial: NCT00601484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo IV, single dose